BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/15/2014 8:54:00 PM | Browse: 1275 | Download: 1537
 |
Received |
|
2013-01-22 09:31 |
 |
Peer-Review Started |
|
2013-01-22 14:14 |
 |
First Decision by Editorial Office Director |
|
|
 |
Return for Revision |
|
2013-03-08 10:22 |
 |
Revised |
|
2013-04-19 10:57 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2013-06-19 12:51 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2013-06-20 00:43 |
 |
Articles in Press |
|
|
 |
Edit the Manuscript by Language Editor |
|
2013-07-05 22:41 |
 |
Typeset the Manuscript |
|
2013-08-08 14:35 |
 |
Publish the Manuscript Online |
|
2013-08-19 18:22 |
| Category |
Infectious Diseases |
| Manuscript Type |
Autobiography |
| Article Title |
Serum proteins in chronic hepatitis B patients treated with peginterferon alfa-2b
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Sunida Kuakarn, Poorichaya SomParn, Pisit Tangkijvanich, Varocha Mahachai, Visith Thongboonkerd and Nattiya Hirankarn |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| 90th Anniversary of Chulalongkorn University Fund (Ratchadaphiseksomphot Endowment Fund) |
|
| Thailand Research Fund |
RMU5180051 |
| Thailand Research Fund Senior Research Scholarship |
RTA5380005 |
| Higher Education Research Promotion and National Research University Project of Thailand, Office of the Higher Education Commission |
HR1163A |
| Integrated Innovation Academic Center, Chulalongkorn University Centenary Academic Development Project |
CU56-HR05 |
| Liver Research Unit, Chulalongkorn University |
|
|
| Corresponding Author |
Nattiya Hirankarn, MD, PhD, Immunology Unit, Department of Microbiology, Faculty of Medicine, Chulalongkorn University, 254 Phayathai Road, Pathumwan, Bangkok 10330, Thailand. nattiyap@gmail.com
|
| Key Words |
Proteomics; Peginterferon alfa-2b; Chronic hepatitis B; Alpha-2-HS-glycoprotein; Serum |
| Core Tip |
Serum proteins serve as non-invasive biomarkers for several diseases. This is the first report on the potential use of common protein levels in the serum of chronic hepatitis B (CHB) patients to predict treatment responsiveness to peginterferon alfa-2b. We identified 2 potential serum biomarkers, alpha-2-HS-glycoprotein and complement component C3c, that can be used to predict treatment outcome in patients with CHB receiving peginterferon alfa-2b. The identification of these biomarkers prior to treatment is preferable in order to avoid systemic side effects due to interferon therapy.
|
| Publish Date |
2013-08-19 18:22 |
| Citation |
Kuakarn S, SomParn P, Tangkijvanich P, Mahachai V, Thongboonkerd V, Hirankarn N. Serum proteins in chronic hepatitis B patients treated with peginterferon alfa-2b. World J Gastroenterol 2013; 19(31): 5067-5075 |
| URL |
http://www.wjgnet.com/1007-9327/full/v19/i31/5067.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v19.i31.5067 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.